WHICH PATIENTS WITH OVARIAN CANCER SHOWS THE COMBINATION OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN

Cover Page
  • Authors: Khokhlova S.V.1, Cherkasova M.V.2, Orel N.F.3, Limareva S.V.1, Bazaeva I.Y.1, Gorbunova V.A.1
  • Affiliations:
    1. N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation
    2. Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation
    3. N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation
  • Issue: Vol 68, No 11 (2013)
  • Pages: 115-121
  • Section: SHORT MESSAGES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/131
  • DOI: https://doi.org/10.15690/vramn.v68i11.852
  • Cite item

Abstract


Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months without an increase in life expectancy. Non-platinum combination of trabectedin with pegylated liposomal doxorubicin has shown comparable efficacy with an advantage in overall survival in patients with platinum-free interval of 6–12 months. A platinum-free interval prolongation by the use of non-platinum mode increases the efficiency of subsequent platinum-based therapy, increasing the life expectancy of patients . Currently under study molecular markers and prognostic factors allowing to define a group of patients who have the greatest benefit from the use trabectedin with pegylated liposomal doxorubicin as second-line chemotherapy.

 


About the authors

S. V. Khokhlova

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation

Author for correspondence.
Email: svkhokhlova@mail.ru

Russian Federation MD, senior research scientist of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

M. V. Cherkasova

Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation

Email: m_cherkasova@mail.ru

Russian Federation postgraduate of the Department of Oncology of RMAPE. Address: 2/1, Barrikadnaya Street, Moscow, RF, 123995; tel.: (499) 252-21-04

N. F. Orel

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation
Russian Medical Academy of Postgraduate Education, Moscow, Russian Federation

Email: orel.nad@yandex.ru

Russian Federation PhD, leading research scientist of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS, professor of the Department of Oncology of RMAPE. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

S. V. Limareva

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation

Email: limareva@yandex.ru

Russian Federation MD, research scientist of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

I. Ya. Bazaeva

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation

Email: irinabazaeva@rambler.ru

Russian Federation postgraduate of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

V. A. Gorbunova

N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation

Email: veragorbounova@mail.ru

Russian Federation PhD, professor, Head of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

References

  1. Davydov M.I., Aksel' E.M. Statistics malignancies in Russia and the CIS in 2009. Vestn. RONTs = Bulletin of ROCC. 2011; 22 (3, App.1): 8–169.
  2. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J.L., Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991; 9: 389–393.
  3. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Brit. J. Cancer. 1989; 59: 650–653.
  4. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 1990; 36: 207–211.
  5. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann. Oncol. 2011; 22 (Suppl. 8): 49–51. doi: 10.1093/annonc/mdr467.
  6. Eisenhauer E.A. Optimal assessment of response in ovarian cancer. Oncol. Lett. 2010; 1 (6): 1021–1023.
  7. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., Wheeler S., Swart A.M., Qian W., Torri V., Floriani I., Jayson G., Lamont A., Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361: 2099–2106.
  8. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave J.A., Wagner U., Stahle A., Stuart G., Kimmig R., Olbricht S., Le T., Emerich J., Kuhn W., Bentley J., Jackisch C., Luck H.J., Rochon J., Zimmermann A.H., Eisenhauer E. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 2006; 24: 4699–4707.
  9. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., Broom C., Scarabelli C., Davidson N., Spanczynski M., Bolis G., Malmström H., Coleman R., Fields S.C., Heron J.F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 1997; 15: 2183–2193.
  10. Trimble E.L., Adams J.D., Vena D., Hawkins M.J., Friedman M.A., Fisherman J.S., Christian M.C., Canetta R., Onetto N., Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 1993; 11: 2405–2410.
  11. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore E.M., Lacave J.A. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001; 19: 3312–3322.
  12. Cantù M.G., Buda A., Parma G., Rossi R., Floriani I., Bonazzi C., Dell'Anna T., Torri V., Colombo N. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 2002; 20: 1232–1237.
  13. Cannistra S.A. Is there a «best» choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer. J. Clin. Oncol. 2002; 20: 1158–1160.
  14. Monk B.J., Herzog T., Kaye S., Krasner C.N., Vermorken J.B., Muggia F.M., Pujade-Lauraine E., Park Y.C., Parekh T.V., Poveda A.M. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd Annual Meeting of the European Society of Medical Oncology. Stockholm. 2008. Abstract LBA3.
  15. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 2010; 9 (8): 2157–2163. doi: 10.1158/1535-7163.MCT-10-0263.
  16. Monk B.J., Dalton H., Benjamin I., Tanović A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr. Pharm. Des. 2012; 18 (25): 3754–3769.
  17. Shoji T., Takatori E., Kaido Y. et al. Usefulness of desensitization protocol for carboplatin hypersensitivity reaction during docetaxel-carboplatintherapy for recurrent ovarian cancer: Case report. 2012. Oncol. Lett. 2010;1 (6): 1021–1023.
  18. D'Incalci M., Galmarini C.M. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol. Cancer Ther. 2008; 7 (1): 10–18. doi: 10.1158/1535-7163.MCT-07-0192.
  19. Avila M.A. Exploratory analysis of nibrin in advanced ovarian cancer (AOC) patients treated in the phase III OVA-301 trial. ASCO. 2013; abstr.5566.
  20. Kurman R.J., Shih I.-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the Paradigm. Hum. Pathol. 2011; 42 (7): 918–931.
  21. Cannistra S.A. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J. Clin. Oncol. 2010; 28 (19): 3101–3103. doi: 10.1200/JCO.2010.29.7077. Epub: 2010 Jun 1.
  22. Germano G., Frapolli R., Belgiovine C. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013; 23 (2): 249–262. doi: 10.1016/j.ccr.2013.01.008.
  23. Sehouli J., Alfaro V., González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Ann. Oncol. 2012; 23 (3): 556–562. doi: 10.1093/annonc/mdr321.
  24. Soares D.G., Machado M.S., Rocca C.J. et al. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol. Cancer Ther. 2011; 10 (8): 1481–1489. doi: 10.1158/1535-7163.MCT-11-0252.

Statistics

Views

Abstract - 371

PDF (Russian) - 189

Cited-By


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies